Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research

Wolfe Research started coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $1,150.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on REGN. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 target price on the stock. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ REGN opened at $756.81 on Friday. The firm has a market cap of $83.17 billion, a PE ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals has a 12-month low of $753.69 and a 12-month high of $1,211.20. The company’s fifty day simple moving average is $985.21 and its 200 day simple moving average is $1,034.89. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the period. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares during the period. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.